Valuation: Aligos Therapeutics, Inc.

Market Cap 76.23L 69.43L 63.98L 58.2L 1.09Cr 71Cr 1.15Cr 7.79Cr 3.09Cr 39Cr 2.86Cr 2.8Cr 121Cr P/E 2026 *
-0.19x
P/E 2027 * -0.22x
Enterprise Value -70.99L -64.65L -59.58L -54.19L -1.02Cr -66Cr -1.07Cr -7.25Cr -2.88Cr -36Cr -2.66Cr -2.61Cr -112.68Cr EV / Sales 2026 *
-0.21x
EV / Sales 2027 * -47x
Free-Float
77.92%
Yield 2026 *
-
Yield 2027 * -
1 day-2.40%
1 week-41.90%
Current month-74.58%
1 month-75.40%
3 months-81.71%
6 months-78.63%
Current year-86.91%
1 week 1.18
Extreme 1.175
2
1 month 1.18
Extreme 1.175
5.38
Current year 1.18
Extreme 1.175
10.49
1 year 1.18
Extreme 1.175
13.69
3 years 1.18
Extreme 1.175
46.8
5 years 1.18
Extreme 1.175
416.5
10 years 1.18
Extreme 1.175
937.75
Manager TitleAgeSince
Chief Executive Officer 64 05/02/2018
Director of Finance/CFO 60 01/06/2020
Chief Tech/Sci/R&D Officer 65 01/05/2018
Director TitleAgeSince
Director/Board Member 64 01/08/2018
Director/Board Member 74 01/08/2018
Chairman 64 -
Date Insider Type Main position Quantity % Market Cap. Importance
09/03/26 Free

Chief Technology Officer

23,310 0.4354%
09/03/26 Free

Controller/Auditor

9,450 0.1765%
09/03/26 Free

Chief Executive Officer

1,05,840 1.9770%
Change 5-day change 1-year change 3-year change Capi.($)
-2.40%-41.90%-86.75%-92.52% 76.23L
-2.49%-3.76%+53.38%+62.10% 6.37TCr
-0.63%-2.91%+6.55%+89.34% 5.86TCr
-2.37%-2.22%+21.77%+84.58% 5.42TCr
-2.19%-6.15%+12.43%+111.40% 4.47TCr
-1.89%-7.28%+9.30%+18.50% 4.05TCr
-0.93%-0.47%+19.34%+41.83% 3.63TCr
+1.11%-6.44%+127.46%+675.37% 3.49TCr
-0.80%+0.61%+76.27%+61.80% 3.23TCr
-2.17%+16.65%-28.89%+479.93% 3.1TCr
Average -1.48%-5.28%+21.08%+153.23% 4TCr
Weighted average by Cap. -1.48%-1.85%+31.82%+155.13%

Financials

2026 *2027 *
Net sales 3.37Cr 3.07Cr 2.83Cr 2.57Cr 4.82Cr 311.78Cr 5.07Cr 34Cr 14Cr 170.29Cr 13Cr 12Cr 534.45Cr 61.78L 56.27L 51.85L 47.16L 88.48L 57Cr 92.99L 6.31Cr 2.51Cr 31Cr 2.32Cr 2.27Cr 98Cr
Net income -7.16Cr -6.52Cr -6.01Cr -5.46Cr -10Cr -662.73Cr -11Cr -73Cr -29Cr -361.98Cr -27Cr -26Cr -1.14TCr -11Cr -10Cr -9.62Cr -8.75Cr -16Cr -1.06TCr -17Cr -117.07Cr -47Cr -579.71Cr -43Cr -42Cr -1.82TCr
Net Debt -1.47Cr -1.34Cr -1.24Cr -1.12Cr -2.11Cr -136.32Cr -2.22Cr -15Cr -5.98Cr -74Cr -5.52Cr -5.41Cr -233.68Cr -30Cr -27Cr -25Cr -23Cr -43Cr -2.76TCr -45Cr -304.57Cr -121.05Cr -1.51TCr -111.88Cr -109.52Cr -4.73TCr
Projected Income Statement - Annual - Aligos Therapeutics, Inc.
Logo Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Employees
82
Date Price Change Volume
20/26/20 $1.220 -2.40% 1,06,836
19/26/19 $1.250 -3.85% 1,06,042
18/26/18 $1.300 -4.41% 1,09,347
17/26/17 $1.360 -18.07% 57,480
16/26/16 $1.660 -20.95% 1,39,603
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Aligos Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.220USD
Average target price
36.88USD
Spread / Average Target
+2,922.54%
  1. Stock Market
  2. Stocks
  3. ALGS Stock